Trial Profile
Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate the Similarity of Efficacy and Safety of LBAL 40mg Subcutaneous Biweekly Injection to Humira 40mg Subcutaneous Biweekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors LG Chem; LG Life Sciences
- 07 Jul 2021 Primary endpoint (DAS28-ESR (change from baseline in disease activity score 28-erythrocyte sedimentation rate)) has been met, as per results published in the Clinical and Experimental Rheumatology.
- 07 Jul 2021 Results published in the Clinical and Experimental Rheumatology
- 12 Mar 2021 Status changed from active, no longer recruiting to completed.